Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells is a research paper published in Blood (2021). On theSindex it has a DataRank of 0.848. It has been cited 284 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.848
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NCI NIH HHS
Grant: P30 CA016672
NCI NIH HHS
Grant: P01 CA148600
NCI NIH HHS
Grant: R01 CA211044
MeSH Terms
Additional file 1 of IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts
Additional file 1 of IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts
Additional file 2 of CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma
Additional file 3 of CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma
Additional file 1 of CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma
Additional file 3 of CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma
Additional file 2 of CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma
Additional file 1 of CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma